Strides Pharma to conduct trials for Covid drug

BENGALURU: Indian pharmaceutical company Strides Pharma Science Ltd said on Thursday it has got regulatory approval to conduct clinical trials of antiviral drug favipiravir, considered a potential treatment for COVID-19.
The Bengaluru-based company has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country, Strides founder and non-executive chairman Arun Kumar said on a post-earnings conference call, without giving any more details.
Strides’ announcement comes after Glenmark Pharmaceuticals Ltd said last month it became the first pharma company in the country to get the nod to conduct favipiravir trials. The Mumbai-based company has initiated late-stage clinical trials and expects study results by July or August.
More on Covid-19
Favipiravir is manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014.
However, on Wednesday, a news agency reported that so far there has been no clear evidence of efficacy for Avigan in treating the novel coronavirus in some clinical trials.
Strides late on Wednesday posted a fourth-quarter consolidated net loss of Rs 207 crore ($27.35 million), as it booked a Rs 113 crore write down of inventory and other expenses related to withdrawal of ranitidine products.
The company’s shares rose as much as 5.3% to a two-week high in early trade, but pared some gains and were last up 1.8% at 0430 GMT.

Prohibida la reproducción parcial o total.  Todos los derechos reservados de Rubicon, Global Trade, Customs & Business Partnership, S.C., del Autor y/o Propietario original de la publicación.  El contenido del presente artículo y/o cualquier otro artículo, texto, boletín, noticia y/o contenido digital, entre otros, ya sea propio o de tercero alguno, publicado en nuestra página de internet u otros medios digitales, no constituye una consulta particular y por lo tanto Rubicon, Global Trade, Customs & Business Partnership, S.C., sus colaboradores, socios, directivos y su autor, no asumen responsabilidad alguna de la interpretación o aplicación que el lector o destinatario le pueda dar.

Share on facebook
Share on twitter
Share on linkedin

Deja un comentario